{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:54:32Z","timestamp":1792079672472,"version":"4.4.0"},"reference-count":40,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministero dello Sviluppo Economico","award":["AMICO program-PoC"],"award-info":[{"award-number":["AMICO program-PoC"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Xeomin\u00ae is a commercial formulation of botulinum neurotoxin type A (BoNT\/A) clinically authorized for treating neurological disorders, such as blepharospasm, cervical dystonia, limb spasticity, and sialorrhea. We have previously demonstrated that spinal injection of laboratory purified 150 kDa BoNT\/A in paraplegic mice, after undergoing traumatic spinal cord injury (SCI), was able to reduce excitotoxic phenomena, glial scar, inflammation, and the development of neuropathic pain and facilitate regeneration and motor recovery. In the present study, as proof of concept in view of a possible clinical application, we studied the efficacy of Xeomin\u00ae in the same preclinical SCI model in which we highlighted the positive effects of lab-purified BoNT\/A. Data comparison shows that Xeomin\u00ae induces similar pharmacological and therapeutic effects, albeit with less efficacy, to lab-purified BoNT\/A. This difference, which can be improved by adjusting the dose, can be attributable to the different formulation and pharmacodynamics. Although the mechanism by which Xeomin\u00ae and laboratory purified BoNT\/A induce functional improvement in paraplegic mice is still far from being understood, these results open a possible new scenario in treatment of SCI and are a stimulus for further research.<\/jats:p>","DOI":"10.3390\/toxins15040248","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T01:33:00Z","timestamp":1680053580000},"page":"248","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Xeomin\u00ae, a Commercial Formulation of Botulinum Neurotoxin Type A, Promotes Regeneration in a Preclinical Model of Spinal Cord Injury"],"prefix":"10.3390","volume":"15","author":[{"given":"Valentina","family":"Mastrorilli","sequence":"first","affiliation":[{"name":"Institute of Biochemistry and Cell Biology, National Council of Research of Italy, Via Ercole Ramarini 32, 00015 Monterotondo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5773-3414","authenticated-orcid":false,"given":"Federica","family":"De Angelis","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Cell Biology, National Council of Research of Italy, Via Ercole Ramarini 32, 00015 Monterotondo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Vacca","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Cell Biology, National Council of Research of Italy, Via Ercole Ramarini 32, 00015 Monterotondo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flaminia","family":"Pavone","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Cell Biology, National Council of Research of Italy, Via Ercole Ramarini 32, 00015 Monterotondo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1399-2152","authenticated-orcid":false,"given":"Siro","family":"Luvisetto","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Cell Biology, National Council of Research of Italy, Via Ercole Ramarini 32, 00015 Monterotondo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5393-4796","authenticated-orcid":false,"given":"Sara","family":"Marinelli","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Cell Biology, National Council of Research of Italy, Via Ercole Ramarini 32, 00015 Monterotondo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1017\/S0033583500003292","article-title":"Structure and function of tetanus and botulinum neurotoxins","volume":"28","author":"Montecucco","year":"1995","journal-title":"Q. Rev. Biophys."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1038\/s41598-018-22842-4","article-title":"Structural characterisation of the catalytic domain of botulinum neurotoxin X\u2014High activity and unique substrate specificity","volume":"8","author":"Masuyer","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrmicro3295","article-title":"Botulinum neurotoxins: Genetic, structural and mechanistic insights","volume":"12","author":"Rossetto","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/164_2020_351","article-title":"Novel Native and Engineered Botulinum Neurotoxins","volume":"263","author":"Steward","year":"2021","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/2338","article-title":"Crystal structure of botulinum neurotoxin type A and implications for toxicity","volume":"5","author":"Lacy","year":"1998","journal-title":"Nat. Struct. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1002\/j.1460-2075.1992.tb05441.x","article-title":"Tetanus toxin is a zinc protein and its inhibition of neurotransmitter release and protease activity depend on zinc","volume":"11","author":"Schiavo","year":"1992","journal-title":"EMBO J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/362318a0","article-title":"SNAP receptors implicated in vesicle targeting and fusion","volume":"362","author":"Whiteheart","year":"1993","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1124\/pr.116.012658","article-title":"Botulinum neurotoxins: Biology, pharmacology, and toxicology","volume":"69","author":"Pirazzini","year":"2017","journal-title":"Pharmacol. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/mds.27072","article-title":"Botulinum toxin: State of the art","volume":"32","author":"Jankovic","year":"2017","journal-title":"Mov. Disord."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Choudhury, S., Baker, M.R., Chatterjee, S., and Kumar, H. (2021). Botulinum Toxin: An Update on Pharmacology and Newer Products in Development. Toxins, 13.","DOI":"10.3390\/toxins13010058"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Spiegel, L.L., Ostrem, J.L., and Bledsoe, I.O. (2020). FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia. Toxins, 12.","DOI":"10.3390\/toxins12050332"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Lewandowski, M., \u015awierczewska, Z., and Bara\u0144ska-Rybak, W. (2022). Off-Label Use of Botulinum Toxin in Dermatology-Current State of the Art. Molecules, 27.","DOI":"10.3390\/molecules27103143"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Yi, K.H., Lee, J.H., Hu, H.W., and Kim, H.J. (2022). Anatomical Proposal for Botulinum Neurotoxin Injection for Glabellar Frown Lines. Toxins, 14.","DOI":"10.3390\/toxins14040268"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/ncpneuro0948","article-title":"Botulinum neurotoxins in the treatment of refractory pain","volume":"4","author":"Jabbari","year":"2008","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.3390\/toxins2122890","article-title":"Botulinum neurotoxin for pain management: Insights from animal models","volume":"2","author":"Pavone","year":"2010","journal-title":"Toxins"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pneurobio.2014.06.001","article-title":"Botulinum toxin A, brain and pain","volume":"119\u2013120","author":"Matak","year":"2014","journal-title":"Prog. Neurobiol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Matak, I., B\u00f6lcskei, K., Bach-Rojecky, L., and Helyes, Z. (2019). Mechanisms of Botulinum Toxin Type A Action on Pain. Toxins, 11.","DOI":"10.3390\/toxins11080459"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.3390\/toxins7093818","article-title":"Botulinum Toxin Type A as a Therapeutic Agent against Headache and Related Disorders","volume":"7","author":"Luvisetto","year":"2015","journal-title":"Toxins"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3389\/fneur.2020.00716","article-title":"Botulinum Neurotoxin for the Treatment of Neuropathic Pain","volume":"11","author":"Egeo","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.2174\/0929867327666200806105024","article-title":"The Mechanisms of Action of Botulinum Toxin Type A in Nociceptive and Neuropathic Pathways in Cancer Pain","volume":"28","author":"Salcedo","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40265-018-0894-6","article-title":"OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine","volume":"78","author":"Frampton","year":"2018","journal-title":"Drugs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/head.13849","article-title":"Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review","volume":"60","author":"Burstein","year":"2020","journal-title":"Headache"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.31083\/j.jin2105141","article-title":"Chronic Migraine: A Narrative Review on the Use of Botulinum Toxin with Clinical Indications and Future Directions","volume":"21","author":"Raciti","year":"2022","journal-title":"J. Integr. Neurosci."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Vacca, V., Madaro, L., De Angelis, F., Proietti, D., Cobianchi, S., Orsini, T., Puri, P.L., Luvisetto, S., Pavone, F., and Marinelli, S. (2020). Revealing the Therapeutic Potential of Botulinum Neurotoxin Type A in Counteracting Paralysis and Neuropathic Pain in Spinally Injured Mice. Toxins, 12.","DOI":"10.3390\/toxins12080491"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"8883","DOI":"10.1038\/s41598-019-45037-x","article-title":"Innovative mouse model mimicking human-like features of spinal cord injury: Efficacy of Docosahexaenoic acid on acute and chronic phases","volume":"9","author":"Marinelli","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_26","first-page":"1","article-title":"Spinal cord injury: Current mammalian models","volume":"4","author":"Kundi","year":"2013","journal-title":"Am. J. Neurosci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1006\/exnr.2001.7721","article-title":"Changes in Metabotropic Glutamate receptor expression following spinal cord injury","volume":"170","author":"Mills","year":"2001","journal-title":"Exp. Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nrn1956","article-title":"Glial inhibition of CNS axon regeneration","volume":"7","author":"Yiu","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12035-012-8287-4","article-title":"Reactive Astrogliosis after spinal cord injury\u2014Beneficial and detrimental effects","volume":"46","author":"Billakanti","year":"2012","journal-title":"Mol. Neurobiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/sj.sc.3101483","article-title":"Post-traumatic inflammation following spinal cord injury","volume":"41","author":"Hausmann","year":"2003","journal-title":"Spinal Cord"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"789","DOI":"10.4103\/1673-5374.131591","article-title":"Spinal cord contusion","volume":"9","author":"Ju","year":"2014","journal-title":"Neural Regen. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.expneurol.2014.02.001","article-title":"Neuroinflammatory contributions to pain after SCI: Roles for central glial mechanisms and nociceptor-mediated host defense","volume":"258","author":"Walters","year":"2014","journal-title":"Exp. Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Rupp, D., Nicholson, G., Canty, D., Wang, J., Rh\u00e9aume, C., Le, L., Steward, L.E., Washburn, M., Jacky, B.P., and Broide, R.S. (2020). OnabotulinumtoxinA Displays Greater Biological Activity Compared to IncobotulinumtoxinA, Demonstrating Non-Interchangeability in Both In Vitro and In Vivo Assays. Toxins, 12.","DOI":"10.3390\/toxins12060393"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5603\/PJNNS.a2021.0027","article-title":"Botulinum toxin type-A preparations are not the same medications\u2014Basic science (Part 1)","volume":"55","author":"Car","year":"2021","journal-title":"Neurol. Neurochir. Pol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Byun, J., Kwak, S., Kwon, J.H., Shin, M., Lee, D.K., Rhee, C.H., Kang, W.H., Oh, J.W., and Cruz, D.J.M. (2022). Comparative Pharmacodynamics of Three Different Botulinum Toxin Type A Preparations following Repeated Intramuscular Administration in Mice. Toxins, 14.","DOI":"10.3390\/toxins14060365"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0304-3959(83)90201-4","article-title":"Ethical guidelines for investigations of experimental pain in conscious animals","volume":"16","author":"Zimmermann","year":"1983","journal-title":"Pain"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuroscience.2006.12.004","article-title":"Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain","volume":"145","author":"Luvisetto","year":"2007","journal-title":"Neuroscience"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bbi.2013.01.088","article-title":"Botulinum toxin A increases analgesic effects of morphine, counters development of morphine tolerance and modulates glia activation and \u03bc opioid receptor expression in neuropathic mice","volume":"32","author":"Vacca","year":"2013","journal-title":"Brain Behav. Immun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.neuroscience.2010.03.035","article-title":"Short but not long-lasting treadmill running reduces allodynia and improves functional recovery after peripheral nerve injury","volume":"168","author":"Cobianchi","year":"2010","journal-title":"Neuroscience"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jneumeth.2006.11.016","article-title":"A new approach to assess function after sciatic nerve lesion in the mouse adaptation of the sciatic static index","volume":"161","author":"Baptista","year":"2007","journal-title":"J. Neurosci. Methods"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/15\/4\/248\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:05:22Z","timestamp":1760123122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/15\/4\/248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["toxins15040248"],"URL":"https:\/\/doi.org\/10.3390\/toxins15040248","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,28]]}}}